ACUTA CAPITAL PARTNERS, LLC

All Holdings — 2025 Q4

AI Portfolio Summary
In 2025 Q4, ACUTA CAPITAL PARTNERS, LLC maintained a portfolio of 35 distinct positions. The most significant new addition to the portfolio was MINERVA NEUROSCIENCE, which now represents 1.94% of the total fund value. They heavily accumulated shares in TERNS PHARMACEUTICAL, increasing their position by 26.7%. Conversely, ACUTA CAPITAL PARTNERS, LLC completely exited their position in TOURMALINE BIO INC.
PCA Score Concentration Risk
Risk ENB
Total Positions
35
Quarter
2025 Q4
Top Holding
TERN (17.5%)
Top 10 Concentration
79.4%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-25 of 35
Stock History Sector / Type Port % Prev % Rank / Prev Conviction Change % Change Influence Shares Mkt Value Avg Cost Price Held 1st Owned Source Source Date Date Reported
TERN
TERNS PHARMACEU...
Healthcare 17.48% 3.90% #1 8
Prev: #9
8.5 134,298 26.7%
P
S
637,095 $25,738,638 2022 Q3 13F Filing 2025-12-31 2026-02-14 (Est.)
PRAX
PRAXIS PRECISIO...
Healthcare 16.62% 2.72% #2 10
Prev: #12
8.5 33,285 66.9%
P
S
83,036 $24,474,031 2023 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
CDTX
CIDARA THERAPEU...
Healthcare 13.37% 14.01% #3 1
Prev: #2
5.0 -52,384 -37.0%
P
S
89,145 $19,691,239 2024 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
OCUL
OCULAR THERAPEU...
Healthcare 8.68% 14.08% #4 3
Prev: #1
4.5 -112,211 -9.6%
P
S
1,052,995 $12,783,359 2022 Q2 13F Filing 2025-12-31 2026-02-14 (Est.)
WHWK
WHITEHAWK THERA...
Healthcare 5.60% 6.70% #5 1
Prev: #4
3.7 no change no change
P
S
3,410,402 $8,253,173 2021 Q3 13F Filing 2025-12-31 2026-02-14 (Est.)
DRUG
BRIGHT MINDS BI...
Healthcare 4.48% 5.32% #6
Prev: #6
2.3 -398 -0.5%
P
S
84,477 $6,592,585 2024 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
CMPX
COMPASS THERAPE...
Healthcare 3.99% 3.04% #7 4
Prev: #11
4.1 253,210 30.1%
P
S
1,093,300 $5,871,021 2025 Q3 13F Filing 2025-12-31 2026-02-14 (Est.)
JAZZ
JAZZ PHARMACEUT...
Healthcare 3.35% 3.42% #8 2
Prev: #10
3.3 3,894 15.5%
P
S
29,008 $4,931,360 2025 Q1 13F Filing 2025-12-31 2026-02-14 (Est.)
INSM
INSMED INC
Healthcare 3.06% 5.74% #9 4
Prev: #5
1.2 -12,714 -32.9%
P
S
25,878 $4,503,807 2014 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
ARGX
ARGEN SE - ADR
Healthcare 2.77% 4.86% #10 3
Prev: #7
1.1 -1,528 -24.0%
P
S
4,851 $4,079,448 2017 Q2 13F Filing 2025-12-31 2026-02-14 (Est.)
SRZN
SURROZEN INC
Healthcare 2.74% 2.38% #11 2
Prev: #13
2.1 no change no change
P
S
178,415 $4,032,179 2025 Q1 13F Filing 2025-12-31 2026-02-14 (Est.)
AMLX
AMYLYX PHARMACE...
Healthcare 2.73% 4.68% #12 4
Prev: #8
2.1 no change no change
P
S
333,258 $4,025,757 2025 Q3 13F Filing 2025-12-31 2026-02-14 (Est.)
NERV
MINERVA NEUROSC...
Healthcare 1.94% #13
Prev: #—
4.3 709,500 no change
NEW
709,500 $2,852,190 2025 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
TNGX
TANGO THERAPEUT...
Healthcare 1.70% #14
Prev: #—
4.2 282,732 no change
NEW
282,732 $2,505,006 2025 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
TSHA
TAYSHA GENE THE...
Healthcare 1.70% 1.54% #15 2
Prev: #17
1.7 no change no change
P
S
454,827 $2,501,549 2023 Q3 13F Filing 2025-12-31 2026-02-14 (Est.)
ZYME
ZYMEWORKS INC
Healthcare 1.43% 1.41% #16 3
Prev: #19
1.6 no change no change
P
S
80,143 $2,110,165 2024 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
OCS
OCULIS HOLDING ...
Healthcare 1.38% 1.85% #17 1
Prev: #16
1.6 no change no change
P
S
101,777 $2,032,487 2025 Q1 13F Filing 2025-12-31 2026-02-14 (Est.)
DSGN
DESIGN THERAPEU...
Healthcare 0.96% #18
Prev: #—
3.9 150,906 no change
NEW
150,906 $1,415,498 2025 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
INBX
INHIBRX BIOSCIE...
Healthcare 0.88% 0.57% #19 4
Prev: #23
1.4 no change no change
P
S
16,377 $1,293,783 2025 Q3 13F Filing 2025-12-31 2026-02-14 (Est.)
UTHR
UNITED THERAPEU...
Healthcare 0.76% 0.99% #20 2
Prev: #22
1.3 no change no change
P
S
2,296 $1,118,726 2018 Q1 13F Filing 2025-12-31 2026-02-14 (Est.)
VSTM
VERASTEM INC
Healthcare 0.75% 1.31% #21 1
Prev: #20
1.3 no change no change
P
S
143,446 $1,107,403 2023 Q2 13F Filing 2025-12-31 2026-02-14 (Est.)
MAZE
MAZE THERAPEUTI...
Healthcare 0.56% #22
Prev: #—
3.7 20,000 no change
NEW
20,000 $828,600 2025 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
MLTX
MOONLAKE IMMUNO...
Healthcare 0.53% #23
Prev: #—
3.7 59,280 no change
NEW
59,280 $781,310 2022 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
STRO
SUTRO BIOPHARMA...
Healthcare 0.53% #24
Prev: #—
3.7 67,451 no change
NEW
67,451 $780,408 2018 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
DNTH
DIANTHUS THERAP...
Healthcare 0.47% 1.02% #25 4
Prev: #21
0.2 -8,292 -33.2%
P
S
16,708 $688,537 2025 Q3 13F Filing 2025-12-31 2026-02-14 (Est.)
TRML
TOURMALINE BIO ...
Unknown 0.00% 13.27%
Sold All 😨
(Was: #3)
0.0 -268,451 -100.0%
CLOSED
$— 2023 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
ASND
ASCENDIS PHA-AD...
Healthcare 0.00% 2.01%
Sold All 😨
(Was: #14)
0.0 -9,792 -100.0%
CLOSED
$— 2015 Q1 13F Filing 2025-12-31 2026-02-14 (Est.)
KRYS
KRYSTAL BIOTECH...
Healthcare 0.00% 1.93%
Sold All 😨
(Was: #15)
0.0 -10,573 -100.0%
CLOSED
$— 2021 Q3 13F Filing 2025-12-31 2026-02-14 (Est.)
COGT
COGENT BIOSCIEN...
Healthcare 0.00% 1.53%
Sold All 😨
(Was: #18)
0.0 -102,907 -100.0%
CLOSED
$— 2025 Q3 13F Filing 2025-12-31 2026-02-14 (Est.)
FULC
FULCRUM THERAPE...
Healthcare 0.00% 0.54%
Sold All 😨
(Was: #24)
0.0 -57,141 -100.0%
CLOSED
$— 2020 Q3 13F Filing 2025-12-31 2026-02-14 (Est.)
Showing 1-25 of 35 holdings

Unlock Full ACUTA CAPITAL PARTNERS, LLC Analysis

PRO subscribers get access to all historical quarters, Excel/CSV exports, Portfolio Concentration Analytics (PCA), and Risk-Based ENB.

Full Historical Quarters
Excel & CSV Export
PCA & Risk-Based ENB
Auto Cost Basis
Position Change Alerts
Price-Held Analytics